文献速递核素与放射性配体治疗放射性药物与辐射防护

靶向C-X-C趋化因子受体4的放射性配体治疗在血液系统恶性肿瘤中的应用——清髓效应、抗淋巴瘤活性与安全性特征

C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile.
PubMed 文献 · Clin Nucl Med · 2023-11-29

21例经重度预处理的血液系统恶性肿瘤患者接受靶向CXCR4的90Y-pentixather放射性配体治疗后,白细胞下降79.4%±18.7%,粒细胞下降70.3%±21%,血小板下降43.1%±36%(与第0天相比P≤0.0005);第2天LDH达峰值后快速下降(峰值与CON日比较P=0.0006),无患者符合肿瘤溶解综合征标准,25例次实验室不良事件中≥3级占2/25(8%)。

要点

  • 靶向CXCR4的放射性配体治疗可实现有效清髓,使患者能够接受造血干细胞移植。
  • 该治疗具有不依赖后续治疗步骤的直接抗淋巴瘤活性,表现为LDH峰值后快速下降。
  • 安全性可接受,未出现肿瘤溶解综合征,≥3级实验室不良事件占2/25(8%)。

核心结论

  • 靶向CXCR4的放射性配体治疗引起有效清髓,使患者能够接受造血干细胞移植。
  • 该治疗还发挥不依赖后续治疗步骤的直接抗淋巴瘤活性,且安全性可接受。

研究设计与样本

  • 21例经重度预处理的血液系统恶性肿瘤患者,在靶向CXCR4的68Ga-pentixafor PET/CT后接受靶向CXCR4的90Y-pentixather放射性配体治疗。
  • 在放射性配体治疗前(第-1天)、治疗当天(第0天)、治疗后2天(第2天)及CON前(中位第10天)检测血液学实验室参数以评估清髓效果。
  • 以乳酸脱氢酶(LDH)水平作为抗淋巴瘤活性的替代标志物,并依据Cairo-Bishop定义筛查实验室定义的肿瘤溶解综合征,采用CTCAE 5.0版记录急性实验室不良事件。

主要发现

  • 放射性配体治疗后至CON前,白细胞水平显著下降79.4%±18.7%,粒细胞下降70.3%±21%,血小板下降43.1%±36%(与第0天相比P≤0.0005)。
  • 放射性配体治疗后LDH水平在第2天已达峰值,随后快速下降(峰值与CON日比较P=0.0006),表明90Y-pentixather具有直接抗淋巴瘤活性。
  • CON日LDH水平也显著低于第-1天(P=0.04),提示放射性配体治疗介导了持久缓解。
  • 无患者符合肿瘤溶解综合征标准,而发现25例次归因于靶向CXCR4治疗的实验室不良事件(≥3级占2/25[8%])。
  • 在后续治疗过程中,全部患者(100%)接受了造血干细胞移植。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After C-X-C motif chemokine receptor 4 (CXCR4)-directed radioligand therapy (RLT), lymphoma patients are scheduled for conditioning therapy (CON) followed by hematopoietic stem cell transplantation (HSCT). We aimed to determine whether CXCR4-RLT can achieve bone marrow ablation and direct antilymphoma activity independent from CON/HSCT and also evaluated the safety profile of this theranostic approach in an acute setting. PATIENTS AND METHODS: After CXCR4-directed 68 Ga-pentixafor PET/CT, 21 heavily pretreated patients with hematological malignancies underwent CXCR4-directed RLT using 90 Y-pentixather. The extent of myeloablative efficacy was determined by investigating hematologic laboratory parameters before RLT (day -1), at the day of RLT (day 0), 2 days after RLT (day 2), and before CON (median day 10). Serving as surrogate marker of antilymphoma activity, lactate dehydrogenase (LDH) levels were also assessed until CON. We also screened for laboratory-defined tumor lysis syndrome after the Cairo-Bishop definition and recorded acute laboratory adverse events using the Common Terminology Criteria for Adverse Events version 5.0. RESULTS: After RLT, we observed a significant decline of leukocyte levels by 79.4% ± 18.7% till CON (granulocytes, drop by 70.3% ± 21%; platelets, reduction by 43.1% ± 36%; P ≤ 0.0005 vs day 0, respectively). After RLT, LDH levels already reached a peak at day 2, which was followed by a rapid decline thereafter (peak vs day of CON, P = 0.0006), indicating that 90 Y-pentixather exhibits direct antilymphoma activity. At day of CON, LDH levels were also significantly lower when compared with day -1 ( P = 0.04), suggestive for durable response mediated by RLT. No patient fulfilled the criteria of tumor lysis syndrome, whereas 25 laboratory adverse events attributable to CXCR4-directed treatment were identified (≥grade 3 in 2/25 [8%]). During further treatment course, all patients (100%) received HSCT. CONCLUSIONS: CXCR4-directed RLT causes effective myeloablation, which allows for HSCT. In addition, it also exerts direct antilymphoma activity independent of subsequent therapeutic steps, whereas safety profile was acceptable.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Dreher N, Dörrler AL, Kraus S, et al. C-X-C Motif Chemokine Receptor 4-Targeted Radioligand Therapy in Hematological Malignancies-Myeloablative Effects, Antilymphoma Activity, and Safety Profile. Clin Nucl Med. 2023. PMID: 38081189. doi:10.1097/RLU.0000000000004974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。